- Forschung
- Karriere
- Aktuelles
- Institut
- Durchsuchen
- Spachumstellung
- Einfache Sprache
„”
Dr.
Head of Screening Unit
Cyclin-Dependent Kinase 18 Controls Trafficking of Aquaporin-2 and Its Abundance through Ubiquitin Ligase STUB1, Which Functions as an AKAP
Cells 2020, 9, E673
online lesenFrom Pyrazolones to Azaindoles: Evolution of Active-Site SHP2 Inhibitors Based on Scaffold Hopping and Bioisosteric Replacement
Journal of Medicinal Chemistry 2020, 63, 14780-14804
online lesenMonensin, a novel potent MYB inhibitor, suppresses proliferation of acute myeloid leukemia and adenoid cystic carcinoma cells
Cancer Letters 2020, 479, 61-70
online lesenEU-OPENSCREEN: A Novel Collaborative Approach to Facilitate Chemical Biology
Slas Discovery 2019, 24, 398-413
online lesenHigh-Throughput Screening for Modulators of CFTR Activity Based on Genetically Engineered Cystic Fibrosis Disease-Specific iPSCs
Stem Cell Reports 2019, 12, 1389-1403
online lesenIdentification of TMEM206 proteins as pore of PAORAC/ASOR acid-sensitive chloride channels
Elife 2019, 8, e49187
online lesenVinylphosphonites for Staudinger-induced chemoselective peptide cyclization and functionalization
Chemical Science 2019, 10, 6322-6329
online lesenDas Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP) gehört zum Forschungsverbund Berlin e.V. (FVB), einem Zusammenschluss von sieben natur-, lebens- und umweltwissenschaftlichen Instituten in Berlin. Die Einrichtungen sind Mitglieder der Leibniz-Gemeinschaft.
Leibniz-Forschungsinstitut für Molekulare Pharmakologie im Forschungsverbund Berlin e.V. (FMP)
Campus Berlin-Buch
Robert-Roessle-Str. 10
13125 Berlin, Deutschland